EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING
SIREN : 490500352
Mitarbeiter: NN (None)Rechtsform: SCA (commandite par actions)Größe: GEGründungsdatum: 2006-06-09 (19 Jahre)Status: AktivBranche: Analyses, essais et inspections techniquesStandort: NANTES (44300), Loire-Atlantique
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING : revenue, balance sheet and financial ratios
EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING is a French company
founded 19 years ago,
specialized in the sector Analyses, essais et inspections techniques.
Based in NANTES (44300),
this company of category GE
shows in 2024 a net income negative of -2.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Historique financier - EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING (SIREN 490500352)
Kennzahl
2024
2023
2022
2021
2020
2019
2018
2017
2016
Umsatz
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Nettoergebnis
-2 446 341 €
-29 097 855 €
9 094 685 €
11 837 507 €
-136 900 €
3 697 462 €
1 834 900 €
1 359 458 €
5 477 521 €
EBITDA
-151 452 €
-14 055 €
-12 495 €
-14 386 €
-15 529 €
-10 991 €
-99 310 €
-12 021 €
-12 362 €
Nettomarge
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Umsatz und Gewinn- und Verlustrechnung
In 2024, EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING records a net loss of 2.4 M€. This deficit will reduce equity on the balance sheet.
EBITDA (2024)
?
EBITDA (Betriebsergebnis vor Abschreibungen)
Definition
Ressource générée par l'activité courante, avant amortissements et charges financières.
Formel
Wertschöpfung - Personalkosten - Steuern
Interpretation
Positiv = rentable Tätigkeit
-151 452 €
EBIT (2024)
?
EBIT (Betriebsergebnis)
Definition
Betriebsergebnis, einschließlich Abschreibungen und Rückstellungen.
Formel
EBITDA - Abschreibungen und Rückstellungen + Auflösungen
-151 326 €
Nettoergebnis (2024)
?
Nettoergebnis
Definition
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Le compte de résultat détaillé n'est pas disponible pour cette entreprise (liasse simplifiée ou données confidentielles).
Évolution graphique
Anzeigen :
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Aktiva
Chargement des données...
Poste
Brutto
Abschr.
Netto
%
Entwicklung
Données de bilan actif non disponibles pour cette entreprise
Passiva
Chargement des données...
Poste
Jahr
%
Entwicklung
Données de bilan passif non disponibles pour cette entreprise
Solvenz- und Verschuldungskennzahlen
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 100%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Verschuldungsgrad (2024)
?
Verschuldungsgrad
Definition
Misst das Verhältnis von Schulden zu Eigenkapital.
Formel
(Finanzschulden / Eigenkapital) x 100
Interpretation
< 50% : Faible 50-100% : Moderat > 100% : Hoch
0.0%
Finanzielle Autonomie (2024)
?
Finanzielle Autonomie
Definition
Anteil des Eigenkapitals an der Gesamtfinanzierung.
Anzahl der Jahre zur Schuldenrückzahlung mit dem Cashflow.
Formel
Dettes financières / CAF
Interpretation
< 3 Jahre : Ausgezeichnet 3-5 Jahre : Angemessen > 5 Jahre : Attention
0.0
Entwicklung der Solvenzkennzahlen EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Kennzahl
2016
2017
2018
2019
2020
2021
2022
2023
2024
Verschuldungsgrad
0.0
0.0
0.0
0.0
0.0
0.391
0.323
0.0
0.0
Finanzielle Autonomie
81.323
99.537
97.142
97.301
280.127
99.599
99.677
99.998
99.989
Rückzahlungsfähigkeit
0.0
0.0
0.0
0.0
0.0
0.054
0.056
0.0
0.0
Cashflow / Umsatz
None%
None%
None%
None%
None%
None%
None%
None%
None%
Positionnement sectoriel
Debt ratio
0.02024
2022
2023
2024
Q1: 0.0
Méd: 9.99
Q3: 48.5
Excellent
In 2024, the debt ratio of EUROFINS BIOPHARMA PRODUC... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
99.99%2024
2022
2023
2024
Q1: 11.63%
Méd: 34.78%
Q3: 58.76%
Excellent+7 pts über 3 Jahre
In 2024, the financial autonomy of EUROFINS BIOPHARMA PRODUC... (100.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
0.0 years2024
2022
2023
2024
Q1: 0.0 years
Méd: 0.0 years
Q3: 0.87 years
Excellent-26 pts über 3 Jahre
In 2024, the repayment capacity of EUROFINS BIOPHARMA PRODUC... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquiditätskennzahlen
The liquidity ratio (= Current assets / Current liabilities) stands at 72669.15. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquiditätsquote (2024)
?
Liquiditätsquote
Definition
Fähigkeit, kurzfristige Schulden mit dem Umlaufvermögen zu decken.
Formel
Umlaufvermögen / Kurzfristige Verbindlichkeiten
Interpretation
> 1.5 : Sehr gut 1-1.5 : Angemessen < 1 : Risque de liquidité
72669.155
Zinsdeckung (2024)
?
Zinsdeckung
Definition
Fähigkeit, Zinsaufwendungen mit dem Betriebsergebnis zu decken.
Entwicklung der Liquiditätskennzahlen EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Kennzahl
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquiditätsquote
1755.103
21887.298
80.986
99.915
26771.667
47648.681
199246.072
103569.145
72669.155
Zinsdeckung
-0.121
-21822.81
-119.481
-1205.095
0.0
-106.339
-357.543
-267839.516
-8268.626
Positionnement sectoriel
Liquidity ratio
72669.152024
2022
2023
2024
Q1: 133.14
Méd: 205.95
Q3: 337.03
Excellent
In 2024, the liquidity ratio of EUROFINS BIOPHARMA PRODUC... (72669.15) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
-8268.63x2024
2022
2023
2024
Q1: 0.0x
Méd: 0.02x
Q3: 2.48x
Watch-23 pts über 3 Jahre
In 2024, the interest coverage of EUROFINS BIOPHARMA PRODUC... (-8268.6x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Umlaufvermögensbedarf und Zahlungsfristen
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 26 days. Favorable situation: supplier credit is longer than customer credit by 26 days.
Operatives Working Capital (2024)
?
Operatives Working Capital
Definition
Besoin de financement généré par le cycle d'exploitation (stocks + créances - dettes fournisseurs).
Frequently asked questions about EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING
What is the revenue of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING ?
The revenue of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING is not publicly disclosed (confidential accounts filed with INPI).
Is EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING profitable?
EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING recorded a net loss in 2024.
Where is the headquarters of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING ?
The headquarters of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING is located in NANTES (44300), in the department Loire-Atlantique.
Where to find the tax return of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING ?
The tax return of EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING operate?
EUROFINS BIOPHARMA PRODUCT TESTING & PROFESSIONAL SCIENTIFIC SERVICES FRANCE HOLDING operates in the sector Analyses, essais et inspections techniques (NAF code 71.20B). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Drehen Sie Ihr Telefon ins Querformat, um das Diagramm anzuzeigen